Focus will be on drug-resistant gram-negative pathogens.
GlaxoSmithKline inked a $41 million agreement from the Defense Threat Reduction Agency of the DoD. The funding, which will be provided over five years, will be used to identify and develop a class of antibacterials targeting gram-negative biothreats and conventional hospital pathogens.
GSK says that it will also contribute to this effort by providing supplemental staff and covering other program costs. The research will focus on gram-negative pathogens such as Pseudomonas, Klebsiella, and Acinetobacter, which are increasingly resistant to all known classes of antibiotics.